Aldeyra Therapeutics

Overview

Aldeyra Therapeutics is a biotechnology company devoted to discovering and developing innovative therapies for immune-mediated diseases. The company's approach focuses on modulating protein systems rather than directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways simultaneously while minimizing toxicity.

Product Pipeline

The company's portfolio includes:

• RASP (Reactive Aldehyde Species) Modulators: ADX-248, ADX-246, and chemically related molecules for systemic and retinal immune-mediated diseases
• Reproxalap: A late-stage RASP modulator candidate for dry eye disease and allergic conjunctivitis
• ADX-2191: A novel intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa

Therapeutic Focus

Aldeyra's development strategy targets immune-mediated conditions not adequately addressed by current treatments, with particular emphasis on ocular and systemic inflammatory diseases. The company advances multiple ongoing clinical trials toward commercialization of next-generation medicines.